Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sanofi - American Depositary Shares (NQ:SNY)

52.09 -0.05 (-0.10%)
Streaming Delayed Price Updated: 10:55 AM EST, Nov 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
39 40 Next >
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗
It's time to start off the final trading day this week with a breakdown of the biggest pre-market stock movers on Friday! 
Via InvestorPlace
News headline image
Nasdaq, S&P 500 Eye Rebound While Bitcoin Edges Down: Amazon's Q3 Lifts Tech Stocks As Traders Eye Fed's Favorite Inflation Gauge ↗
As Amazon, Inc. (NASDAQ:AMZN) hawked good tidings, the negative sentiment in the equity market appears to have reversed. The recovery could be in part due to traders looking for bargains following a... 
Via Benzinga
Topics Economy Stocks
News headline image
Ford, Sanofi, Enphase Energy And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
U.S. stock futures traded higher this morning on Friday. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
News headline image
Looking Into Sanofi's Recent Short Interest ↗
 
Via Benzinga
News headline image
Preview: Sanofi's Earnings ↗
 
Via Benzinga
News headline image
(SNY) - Analyzing Sanofi's Short Interest ↗
 
Via Benzinga
Acurx Pharmaceuticals Share Price And Volume Are Surging Ahead Of Phase 2b Trial Data Release ($ACXP)
Via AB Newswire
Topics Death
News headline image
Earnings Scheduled For October 27, 2023 ↗
Companies Reporting Before The Bell • Sanofi (NASDAQ:SNY) is projected to report quarterly earnings at $2.26 per share on revenue of $12.56 billion. 
Via Benzinga
News headline image
What's Going On With Mirati Therapeutics Stock? ↗
Mirati Therapeutics, Inc. (NASDAQ: MRTX) shares are trading higher Friday. 
Via Benzinga
News headline image
Sanofi Stock Relative Strength Rating Jumps To 84: One To Watch ↗
Additionally, Sanofi stock has a decent 83 Composite Rating out of 99, and an 80 Earnings Per Share Rating. 
Via Investor's Business Daily
Why the Relapsed/Refractory Acute Myeloid Leukemia Market is Expected to Witness Revolutionary Developments
EQNX::TICKER_START (NASDAQ:TCBP),(NYSE:CVM),(NASDAQ:INVO),(NASDAQ:SNY),(NYSE:PFE) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Roche Spends $7.1 Billion On Roivant Drug, Following Merck, Sanofi Into The Raging Hot Immunology Space ↗
Roche is joining Merck and Sanofi in the TL1A drug space. These drugs could treat stomach diseases. 
Via Investor's Business Daily
News headline image
Amazon, Alphabet, Meta, Intel Q3 Earnings This Week: Will Mega-Caps Shatter Forecasts And Revive Market? ↗
Factset data indicates that out of the 17% of the S&P 500 companies that have reported so far, 73% have reported positive EPS surprises. 
Via Benzinga
Topics Stocks
News headline image
Dupixent® (dupilumab) Phase 3 Results Show Sustained Efficacy for Up to One Year in Children 1 to 11 Years of Age with Eosinophilic Esophagitis (EoE)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Sanofi Bridging the Gap between the Homeless and Society via Futsal
From sanofi-aventis Korea
Via Business Wire
News headline image
Pfizer, Sanofi's Respiratory Syncytial Virus Products Faces Insurance And Logistical Hurdles To Protect Infants ↗
As the respiratory virus season kicks off, healthcare providers are racing against time to offer Pfizer Inc's (NYSE: PFE) vaccine, Abrysvo, to pregnant patients and Sanofi SA's (NASDAQ:  
Via Benzinga
News headline image
2 Healthcare Stocks Near 52-Week Highs Still Worth Buying ↗
These two large-cap biopharma companies could have more room to run. 
Via The Motley Fool
News headline image
Week In Review: Two China Biopharmas Announce Billion Dollar Deals ↗
MediLink Therapeutics out-licensed global rights for its antibody-drug conjugate candidate to BioNTech in a $1.1 billion agreement. Meanwhile, BioMap formed a collaboration with Sanofi in a deal with... 
Via Talk Markets
News headline image
2 Surefire Stocks That Could Make You Richer ↗
It won't happen overnight, but with these stocks, a little patience is all you need. 
Via The Motley Fool
News headline image
Mirati Therapeutics Snags $5.8 Billion Takeover Deal, But Shares Fall On Lowball Bid ↗
Bristol Myers Squibb hopes to buy Mirati Therapeutics for up to $5.8 billion. 
Via Investor's Business Daily
News headline image
Amgen's Adcomm Meeting Paves Way To Launch Boost For Mirati Therapeutics' Lung Cancer Drug: Analysts ↗
According to a report on Thursday, French pharma company Sanofi SA (NASDAQ: SNY) is reportedly exploring a potential acquisition of cancer drugmaker Mirati Therapeutics Inc (NASDAQ: MRTX). 
Via Benzinga
News headline image
Palantir And PwC Team Up To Accelerate Data-Driven Operations, OpenAI Rival Secures Billions In Big Tech Backing, Six US States Brace For Healthcare Strike: Today's Top Stories ↗
Benzinga 
Via Benzinga
News headline image
Teva Pharma Hooks Sanofi In $1.5 Billion Inflammation Deal. But Shares Tumble. ↗
The deal leans into the emerging TL1A drug class, potentially rivaling Roivant and Merck. 
Via Investor's Business Daily
News headline image
Sanofi, Teva Pledge $1.5B To Target Inflammatory Bowel Disease That Impacts Almost 10M People ↗
Sanofi SA (NASDAQ: SNY) and Teva Pharmaceutical Industries Ltd (NYSE: TEVA) have collaborated to co-develop and  
Via Benzinga
News headline image
Tiziana Advances Phase 2 Site Selection For Its Lead Clinical Program In Non-Active Secondary Progressive Multiple Sclerosis (SPMS) And The Company Prepares For Six-Month Clinical Data Update ↗
Tiziana Life Sciences Ltd. (NASDAQ: TLSA) recently announced the Company has initiated site selection for its lead intranasal anti-CD3 monoclonal antibody drug c 
Via Benzinga
News headline image
Sanofi and Teva Announce Exclusive Collaboration to Deliver Inflammatory Bowel Disease Treatment
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Why Shares of Kymera Therapeutics Jumped on Tuesday ↗
The company had a big bounce after hitting a 52-week low the day before. 
Via The Motley Fool
News headline image
'Airbnb Has Foundational Cracks', Disney+ Follows Netflix On Subscription Sharing Crackdown, Microsoft's Nadella Criticizes Google's Exclusive Content Deals: Today's Top Stories ↗
Benzinga 
Via Benzinga
News headline image
Pharma Giants Sanofi, Johnson & Johnson Join Forces To Develop E.coli Vaccine ↗
Sanofi SA (NASDAQ: SNY) struck a deal with Janssen Pharmaceuticals, a unit of Johnson & Johnson (NYSE: JNJ), to develop and commercialize the vaccine candidate for extraintestinal&nb 
Via Benzinga
News headline image
AstraZeneca Settles Heartburn Treatment Lawsuit For One Of Biggest Selling Drug ↗
AstraZeneca Plc (NASDAQ: AZN) has  
Via Benzinga
Topics Lawsuit
< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
39 40 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.